ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.34 +0.42%

+$0.04 today

Market cap
$2.96B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.62M

Average 7.07M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$50.40M

FY 2025 · Annual

-57.5% YoY

Investing Cash Flow

-$21.89M

FY 2025 · Annual

Financing Cash Flow

-$44.02M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
Deferred Income Tax220.76K00(84.28M)11.02M
Stock-Based Compensation3.49M5.22M6.19M13.62M20.03M
Change in Working Capital(51.68M)(18.29M)(10.12M)(18.54M)(139.6M)
Accounts Receivables(15.34M)13.07M(11.92M)(22.58M)(108.43M)
Inventory(43.19M)(38.56M)(9.63M)2.67M(36.23M)
Accounts Payables1.36M799.98K3.84M4.15M2.33M
Other Working Capital5.49M6.4M7.58M(2.78M)2.74M
Other Non-Cash Items1.75M12.35M32.64M2.16M3.92M
Operating Cash Flow(112.37M)(59.51M)8.8M118.67M50.4M
Capital Expenditures(13.51M)(13.91M)(4.98M)(8.58M)(22.58M)
Acquisitions (Net)00001M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(210K)(349K)(316K)
Investing Cash Flow(13.51M)(13.91M)(4.98M)(8.58M)(21.89M)
Debt Repayment(34K)51.71M(23.6M)(60M)(3.18M)
Common Stock Issued121.14M64.65M07.49M2.98M
Common Stock Repurchased00(1.42M)0(31.94M)
Dividends Paid00000
Other Financing Activities(62K)(7.51M)(13.97M)(5.8M)(11.89M)
Financing Cash Flow121.05M108.85M(38.99M)(58.3M)(44.02M)
Effect of Forex Changes00000
Net Change in Cash(4.83M)35.43M(35.17M)51.8M(15.52M)
Free Cash Flow(125.88M)(73.42M)3.82M110.1M27.82M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$146.9M
+ D&A$8.1M
+ Stock-Based Comp$20.0M
+ Deferred Tax$11.0M
- Working Capital-$139.6M
+ Other Non-Cash$3.9M
= Operating Cash Flow$50.4M
- Capex-$22.6M
= Free Cash Flow$27.8M

Analysis

FY2025 free cash flow is $27.8M. FCF conversion is 18.9% of net income. Operating cash flow was $50.4M, with capex of -$22.6M. The largest bridge item is Working Capital at -$139.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026
SC 13GSC 13G filingAug 7, 2026

Does ADMA generate free cash flow?

ADMA Biologics, Inc. (ADMA) generated $27.82M of free cash flow in fiscal 2025.

How much operating cash flow does ADMA produce?

Operating cash flow was $50.40M, before capital expenditures of $22.57M.